First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with…
Browsing: ESMO Asia Congress 2019
Combination of immunotherapy and VEGF inhibitor improves survival in hepatocellular carcinoma
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall…